[{"address1": "2955 Virtual Way", "address2": "Suite 480", "city": "Vancouver", "state": "BC", "zip": "V5M 4X6", "country": "Canada", "phone": "778-731-1711", "website": "https://www.nervgen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. William Joseph Radvak BASc", "age": 60, "title": "Co-Founder & Chairman", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 168103, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harold Martin Punnett D.M.D.", "title": "Co-Founder & Independent Director", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William J. Adams C.A., CPA, CA, CPA", "age": 61, "title": "CFO & Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 280466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel D. Mikol M.D., Ph.D.", "title": "Chief Medical Officer", "fiscalYear": 2022, "totalPay": 471561, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Kelly", "age": 57, "title": "CEO, President & Director", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  McAlister", "title": "Co-Founder & Advisor", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.92, "open": 1.95, "dayLow": 1.85, "dayHigh": 1.968, "regularMarketPreviousClose": 1.92, "regularMarketOpen": 1.95, "regularMarketDayLow": 1.85, "regularMarketDayHigh": 1.968, "beta": 1.572, "volume": 19165, "regularMarketVolume": 19165, "averageVolume": 60750, "averageVolume10days": 32490, "averageDailyVolume10Day": 32490, "marketCap": 117843184, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 2.515, "fiftyDayAverage": 1.57688, "twoHundredDayAverage": 1.38343, "currency": "USD", "enterpriseValue": 101471168, "floatShares": 46589940, "sharesOutstanding": 59506400, "heldPercentInsiders": 0.21473, "heldPercentInstitutions": 6.0000002e-05, "impliedSharesOutstanding": 60432400, "bookValue": 0.086, "priceToBook": 22.674417, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -19713896, "trailingEps": -0.24, "enterpriseToEbitda": -5.156, "52WeekChange": 0.34265733, "SandP52WeekChange": 0.21733451, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "NGENF", "underlyingSymbol": "NGENF", "shortName": "NERVGEN PHARMA CORP", "longName": "NervGen Pharma Corp.", "firstTradeDateEpochUtc": 1554298200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c643fe7c-bc4e-3aef-b13f-5cf62f2bcc81", "messageBoardId": "finmb_577702483", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.95, "recommendationKey": "none", "totalCash": 14785554, "totalCashPerShare": 0.248, "ebitda": -19679876, "totalDebt": 219242, "quickRatio": 1.331, "currentRatio": 1.402, "debtToEquity": 4.293, "returnOnAssets": -0.54390997, "returnOnEquity": -1.67633, "freeCashflow": -6639701, "operatingCashflow": -13263048, "financialCurrency": "CAD", "trailingPegRatio": null}]